Search
Etripamil
go.drugbank.com/drugs/DB12605ApprovedInvestigational[A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT
Tegafur-uracil
go.drugbank.com/drugs/DB09327Approved[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.
Corticosterone
go.drugbank.com/drugs/DB04652Investigational(From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437)
Autologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase
go.drugbank.com/drugs/DB18681ExperimentalIt comprises autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) that had been genetically modified ex vivo with EFS-ADA LV.
Resveratrol
go.drugbank.com/drugs/DB02709InvestigationalIt is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as cis-(Z) and trans-(E) isomers.
Synonyms: (E)-resveratrol, (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediolSPP 301
go.drugbank.com/drugs/DB05290InvestigationalSPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy.
Choline alfoscerate
go.drugbank.com/drugs/DB04660Investigational(From Stedman, 26th ed) It counteracts the effects of urea on enzymes and other macromolecules. [PubChem]
Nadolol
go.drugbank.com/drugs/DB01203ApprovedInvestigational[A34177] Nadolol was granted FDA approval on 10 December 1979.[L7922]